JT Signs an Exclusive License Agreement with Dermavant to Develop and Commercialize Tapinarof in Japan
Shots:
- Dermavant to receive $60M up front- up to $53M as development milestones and royalties on sales of the tapinarof in psoriasis and AD. JT and its subsidiary- Torii Pharmaceutical to get rights to develop & commercialize tapinarof for psoriasis and AD in Japan
- Additionally- JT has signed an exclusive license agreement with Torii to co-develop and commercialize tapinarof in Japan
- Tapinarof (qd) is an investigational therapeutic aryl hydrocarbon receptor modulating agent (TAMA)- currently being evaluated in two P-III studies for psoriasis in the US and P-II studies for both psoriasis and AD with its expected NDA filing for PsO to the US FDA in 2021
Click here to read full press release/ article | Ref: GlobeNewswire | Image: Cmocro
This content piece was prepared by our former Senior Editor. She had expertise in life science research and was an avid reader. For any query reach out to us at connect@pharmashots.com
